FAQ Library

FAQ Library published on January 31, 2017
Join Dr. Rami Komrokji as he discusses the most common challenges in the diagnosis of MDS, including cytopenias, flow cytometry, and molecular data.
FAQ Library published on November 9, 2016
Join Dr. David Steensma as he explains how age affects survival outcomes in patients with MDS.
FAQ Library published on October 13, 2016
Join Dr. David Steensma as he discusses the impact of age and frailty when considering hematopoietic stem cell transplant in MDS patients.
FAQ Library published on September 15, 2016
Join Dr. Garcia-Manero as he explains whether or not a patient with low-risk MDS can develop into a patient with high-risk disease even though their treatment seems to be working.
FAQ Library published on August 9, 2016
Dr. Smith discusses the genetic mutations that can occur over the course of MDS, some of which are associated with poorer outcomes, such as the transition to AML.
FAQ Library published on July 26, 2016
Keeping patients on their MDS treatment for as long as possible is critical. Dr. Smith discusses several key approaches clinicians can use to increase compliance and longevity of therapy.
FAQ Library published on June 8, 2016
In this frequently asked question, Dr. Doug Smith discusses how molecular markers such as TP53 are changing how we treat MDS.
FAQ Library published on May 12, 2016
Join Dr. Hetty Carraway as she describes how to effectively address the option of active therapy with a patient who only wants supportive care.
FAQ Library published on May 5, 2016
There are two major studies that are exploring immunotherapy for MDS and both have had consistent results.
FAQ Library published on May 5, 2016
Once you understand the knowledge your patient has, you can then begin to explain the seriousness of the individual situation.
Page 2 of 6
Results 11 - 20 of 60

Managing MDS would like to recognize and thank Celgene Corporation for their educational support of ManagingMDS.com

©2017 MediCom Worldwide, Inc. All rights reserved